Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE9A | O76083 | 20/20 | 0.81 |
| ▸ | PDE1C | Q14123 | 1/20 | 0.65 |
| ▸ | PDE1B | Q01064 | 6/20 | 0.56 |
| ▸ | PDE5A | O76074 | 2/20 | 0.55 |
| ▸ | PDE2A | O00408 | 1/20 | 0.55 |
| ▸ | PDE8A | O60658 | 1/20 | 0.55 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.55 |
| ▸ | PDE7A | Q13946 | 1/20 | 0.55 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12401048 | 0.99 | PDE9A (0.79) | PDE9APDE1CPDE1BPDE5APDE2A | |
| SCHEMBL6343967 | 0.90 | PDE9A (0.66) | PDE9APDE1CPDE1BPDE5APDE7A | |
| SCHEMBL7880512 | 0.90 | PDE9A (0.67) | PDE9APDE1C | |
| SCHEMBL2528957 | 0.90 | PDE9A (1.00) | PDE9APDE1CPDE1BPDE5A | |
| SCHEMBL7884874 | 0.89 | PDE9A (0.66) | PDE9APDE1CPDE1BPDE5A | |
| SCHEMBL12401082 | 0.89 | PDE9A (0.98) | PDE9APDE1CPDE1B | |
| SCHEMBL6338426 | 0.89 | PDE9A (0.65) | PDE9A | |
| SCHEMBL2528350 | 0.88 | PDE9A (0.71) | PDE9APDE1CPDE1BPDE5APDE2A | |
| SCHEMBL7876695 | 0.88 | PDE9A (0.64) | PDE9APDE1CPDE1B | |
| SCHEMBL2528553 | 0.88 | PDE9A (0.73) | PDE9APDE1CPDE1BPDE5APDE2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8623879-B2 | 1-heterocyclyl-1,5-dihydro-pyrazolo[3,4-D] pyrimidin-4-one derivates and their use as PDE9A modulators | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-01-07 | — | — | US | disclosed |
| US-20110184000-A1 | 1-HETEROCYCLYL-1,5-DIHYDRO-PYRAZOLO[3,4-D] PYRIMIDIN-4-ONE DERIVATES AND THEIR USE AS PDE9A MODULATORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-07-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110184000-A1 | 1-HETEROCYCLYL-1,5-DIHYDRO-PYRAZOLO[3,4-D] PYRIMIDIN-4-ONE DERIVATES AND THEIR USE AS PDE9A MODULATORS | PDE9A, PDE7A, PDE1A | PDE9A 1/4885PDE1C 6/4885PDE1B 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.